Bone Cancer Surgery Prospective Database

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorSecond Affiliated Hospital, School of Medicine, Zhejiang University

About this trial

According to the Global Burden of Disease Report, the number of cancer patients worldwide is increasing year by year. In 2023, there were a total of 18.5 million newly confirmed cases of malignant tumors worldwide, and it is expected to grow to 30.5 million cases by 2050. Among them, the number of new cases of malignant tumors of bone and articular cartilage increased by 86.4% from 1990 to 2023. Meanwhile, bone is a particularly common site for tumor metastasis, and almost half of cancer patients are at risk of developing bone metastasis. Surgical resection is the main treatment method for both primary and secondary bone cancer. For patients with bone cancer, the main goal of surgical treatment is to maintain the patient's function and mobility by relieving pain, preventing impending fractures and/or nerve compression, or stabilizing pathological fractures. Surgery for bone cancer often requires extensive exploration, osteotomy, and prosthetic reconstruction, resulting in significant surgical trauma. The incidence of postoperative complications remains high. The occurrence of postoperative complications can increase patient pain, prolong hospitalization time, increase medical costs, and even endanger life. Therefore, reduction of complications and optimizing perioperative management are key issues that urgently need to be addressed in clinical practice.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Clinical diagnosis of bone cancer

Scheduled to undergo elective bone cancer resection surgery

Disqualifiers

Unable to comply with follow-up

declined participation in the study

Trial population

patients undergoing elective bone cancer resection surgery

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Bone cancer surgery

    Procedure/Surgery

    patients receive surgery based on the doctor's discretion and the consideration of the patients and their family

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Complication

This includes embolic events, pulmonary complication, wound complication, acute kidney injury, death. Diagnose according to radiologic examination, sign and symptom

Time frame
hospital discharge, an average of 10 days

Secondary outcomes

1

The rate of perioperative transfusion of allogeneic blood products

This includes blood products such as plasma and platelets, erythrocytes

Time frame
hospital discharge, an average of 10 days
2

Wound drainage volume

Accumulated postoperative wound drainage volume

Time frame
hospital discharge, an average of 10 days
3

The coagulation function tests during the perioperative period

This includes thromboelastography result

Time frame
hospital discharge, an average of 10 days
4

Hemoglobin levels

Hemoglobin levels during hospitalIzation

Time frame
hospital discharge, an average of 10 days

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: